NASDAQ:HALO - Halozyme Therapeutics Stock Price, Forecast & News

Halozyme Therapeutics trades on the NASDAQ under the ticker symbol "HALO."

Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced its quarterly earnings results on Tuesday, November, 12th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by $0.05. The biopharmaceutical company had revenue of $46.20 million for the quarter, compared to the consensus estimate of $54.96 million. Halozyme Therapeutics had a negative net margin of 19.73% and a negative return on equity of 15.76%. The company's revenue for the quarter was up 80.5% on a year-over-year basis. During the same period in the prior year, the business earned ($0.19) earnings per share. View Halozyme Therapeutics' Earnings History.

Halozyme Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, February 20th 2020. View Earnings Estimates for Halozyme Therapeutics.

Halozyme Therapeutics issued an update on its FY20 earnings guidance on Tuesday, January, 14th. The company provided earnings per share guidance of $0.60-0.70 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.56. The company issued revenue guidance of $230-245 million, compared to the consensus revenue estimate of $224.10 million.

5 analysts have issued 12 month target prices for Halozyme Therapeutics' shares. Their forecasts range from $16.00 to $27.00. On average, they anticipate Halozyme Therapeutics' share price to reach $22.40 in the next twelve months. This suggests a possible upside of 17.5% from the stock's current price. View Analyst Price Targets for Halozyme Therapeutics.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Halozyme Therapeutics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Halozyme Therapeutics.

Media coverage about HALO stock has trended extremely negative recently, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Halozyme Therapeutics earned a media sentiment score of -4.5 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the near term. View News Stories for Halozyme Therapeutics.

Some companies that are related to Halozyme Therapeutics include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Halozyme Therapeutics investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), NIC (EGOV), Micron Technology (MU), Allergan (AGN), Gilead Sciences (GILD) and Aegean Marine Petroleum Network (ANW).

Halozyme Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Campbell & CO Investment Adviser LLC (0.08%), Strs Ohio (0.04%), TIAA FSB (0.04%), Nisa Investment Advisors LLC (0.01%) and Zurcher Kantonalbank Zurich Cantonalbank (0.01%). Company insiders that own Halozyme Therapeutics stock include Dimitrios Chondros and Randal J Kirk. View Institutional Ownership Trends for Halozyme Therapeutics.

HALO stock was sold by a variety of institutional investors in the last quarter, including Strs Ohio. View Insider Buying and Selling for Halozyme Therapeutics.

HALO stock was bought by a variety of institutional investors in the last quarter, including Campbell & CO Investment Adviser LLC, TIAA FSB, Zurcher Kantonalbank Zurich Cantonalbank and Nisa Investment Advisors LLC. View Insider Buying and Selling for Halozyme Therapeutics.

Shares of HALO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of HALO stock can currently be purchased for approximately $19.07.

Halozyme Therapeutics has a market capitalization of $2.79 billion and generates $151.86 million in revenue each year. The biopharmaceutical company earns $-80,330,000.00 in net income (profit) each year or ($0.56) on an earnings per share basis. Halozyme Therapeutics employs 281 workers across the globe.View Additional Information About Halozyme Therapeutics.

The official website for Halozyme Therapeutics is http://www.halozyme.com/.

Halozyme Therapeutics' mailing address is 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-794-8889 or via email at [email protected]